Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...
Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ...
REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...
Hosted on MSN
Replimune Stock Plunged 42% Today – Here’s Why
Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results